Cyclosporine Market 2026 forecast signals growth to $5.46 billion by 2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Cyclosporine Market Over The 2026–2030 Period?

The cyclosporine market has witnessed significant expansion in recent years. It is anticipated to increase from $2.98 billion in 2025 to $3.37 billion in 2026, growing at a compound annual growth rate (CAGR) of 13.0%. The historical growth of this market can be attributed to an increase in organ transplant procedures, its established effectiveness in immune suppression, the rising occurrence of autoimmune diseases, initial regulatory approvals, and the expanded implementation of hospital-based immunotherapy.

The cyclosporine market size is anticipated to experience rapid expansion in the coming years. It is forecast to reach $5.46 billion by 2030, achieving a compound annual growth rate (CAGR) of 12.8%. This projected growth during the forecast period can be attributed to the rising prevalence of chronic autoimmune conditions, the increasing burden of ophthalmic diseases, improved transplant survival rates, the wider availability of generic medications, and the growing utilization of outpatient immunosuppressive therapies. Major trends expected in this period include the expanding application in autoimmune disease management, the growing adoption of ophthalmic cyclosporine formulations, a rising demand for long-term immunosuppressive treatments, increased deployment in organ transplant maintenance regimens, and the proliferation of generic cyclosporine products.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23360&type=smp

What Underlying Factors Are Accelerating The Growth Of The Cyclosporine Market?

An increasing incidence of autoimmune conditions is anticipated to fuel the expansion of the cyclosporine market in the coming years. These diseases are characterized by the immune system erroneously attacking the body’s own healthy cells, leading to inflammation, tissue damage, and persistent health issues. The uptick in autoimmune disease prevalence stems from genetic predisposition, with improved genetic testing identifying more people at hereditary risk, thereby increasing their vulnerability to such conditions. Cyclosporine demonstrates efficacy in managing autoimmune diseases by inhibiting T-cell activation, which consequently lessens detrimental immune responses against healthy tissues in illnesses like rheumatoid arthritis, psoriasis, and lupus. For example, in October 2024, a thorough review appearing in Signal Transduction and Targeted Therapy, a journal from Nature, a UK-based peer-reviewed scientific publisher, reported that around 8.4 million individuals globally are affected by rheumatoid arthritis, and its overall incidence rate is growing by 2-3% per year; employing the Markov model approach, the number of affected individuals is forecasted to be about 13.5-17.4 million by 2040. Consequently, the expanding occurrence of autoimmune diseases is a key driver for the cyclosporine market’s growth.

How Is The Cyclosporine Market Segmented Across Key Categories?

The cyclosporine market covered in this report is segmented –

1) By Indication: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye, Other Indications

2) By Dosage Form: Capsule, Eye Drops, Liquid Solutions, Creams And Ointments

3) By Route Of Administration: Oral, Topical, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-Users: Hospitals, Homecare, Speciality Centres, Other End-Users

Subsegments:

1) By Transplant Rejection Prophylaxis: Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant, Other Transplants

2) By Rheumatoid Arthritis: Moderate Rheumatoid Arthritis, Severe Rheumatoid Arthritis

3) By Psoriasis: Plaque Psoriasis, Erythrodermic Psoriasis, Guttate Psoriasis, Pustular Psoriasis

4) By Autoimmune Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis

5) By Dry Eye: Chronic Dry Eye, Severe Dry Eye

6) By Other Indications: Atopic Dermatitis, Uveitis, Nephrotic Syndrome, Inflammatory Bowel Disease (IBD)

Which Upcoming Trends Are Expected To Influence The Cyclosporine Market?

Leading companies in the cyclosporine market are concentrating on securing regulatory clearances to expand their product offerings and strengthen their market position. Such regulatory endorsements affirm the safety and effectiveness of cyclosporine, allowing market entry and fostering greater confidence among both prescribers and patients. For instance, in June 2023, Novaliq GmbH, a biopharmaceutical company based in Germany, obtained approval from the U.S. FDA for VEVYE (cyclosporine ophthalmic solution) 0.1%, a distinctive water-free ophthalmic medicine formulated for addressing dry eye disease (DED). This is the inaugural and sole cyclosporine-derived solution for this condition, demonstrating efficacy within just four weeks. VEVYE incorporates an innovative water-free technology named EyeSol, which improves cyclosporine’s bioavailability and its retention time on the ocular surface without requiring preservatives, oils, or surfactants. The solution operates as a calcineurin inhibitor, assisting in the reduction of inflammation connected to dry eye disease.

Who Are The Dominant Players Shaping The Cyclosporine Market Landscape?

Major companies operating in the cyclosporine market are Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Apotex Inc., Cipla Ltd, Dr. Reddy’s Laboratories Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Taj Pharmaceuticals Limited, Panacea Biotec Ltd, Novaliq GmbH, Simson Pharma Limited, Strides Pharma Science Ltd, AdvaCare Pharma, JoinHub Pharma, Grevis Pharmaceuticals Pvt Ltd, GMT Pharma International, Logos Pharma.

Read the full cyclosporine market report here:

https://www.thebusinessresearchcompany.com/report/cyclosporine-global-market-report

Which Region Is Projected To Dominate The Cyclosporine Market During The Forecast Period?

Asia-Pacific was the largest region in the cyclosporine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the cyclosporine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cyclosporine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23360&type=smp

Browse Through More Reports Similar to the Global Cyclosporine Market 2026, By The Business Research Company

Interstitial Cystitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/interstitial-cystitis-drugs-global-market-report

Cyclohexylbenzene Market Report 2026

https://www.thebusinessresearchcompany.com/report/cyclohexylbenzene-global-market-report

Cyclin Dependent Kinase Cdk 4 Or 6 Inhibitor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cyclin-dependent-kinase-cdk-4-or-6-inhibitor-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795